Alfasigma S.p.A.   Report issue

For profit Phase 2 Phase 3 Phase 4
Founded: MIlan Italy (2015)
Status: No NME R&D (2015)

Organization Overview

First Clinical Trial
2015
NCT02512601
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

ALFASIGMA | Alfasigma S.p.A. | Bama GeVe, S.L.U. | Clinedem

Active Ingredients

Marketed Drugs (1)

tegaserod (zelnorm) (2002)

Drugs in Phase 4 Trials (4)

Key: Alfasigma S.p.A. (3) Acquired (1)

obeticholic acid (ocaliva) (21 trials)

polyethylene glycol (1 trial)

simethicone (IMODIUM) (1 trial)

sulodexide (Aterina) (3 trials)

Drugs in Phase 3 Trials (1)

rifaximin (xifaxan) (4 trials)

Drugs in Phase 2 Trials (4)

Key: Alfasigma S.p.A. (0) Acquired (4)

atorvastatin (lipitor) (1 trial)

bezafibrate (Bezalip) (2 trials)

int-787 (1 trial)

ursodeoxycholic acid (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Crohn Disease (Phase 2)

Diverticulitis (Phase 3)

Postphlebitic Syndrome (Phase 4)

Postthrombotic Syndrome (Phase 4)

Recurrence (Phase 2)

Rosacea (Phase 2)

Syndrome (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 30
  • # of Trial APIs: 9